Healthy women
Conditions
Interventions
Intake of foods containing pea-derived ferritin iron
Intake of Placebo
Sponsors
Anti-Aging Pro Corporation
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Women who experience iron deficiency on a daily basis (anemia symptoms) (2) Premenopausal women (3) Women with a BMI of less than 30 kg/m2 (4)Those whose menstruation is in a designated cycle (within 1 week of the end of menstruation on July 28 and 29: follicular phase, end of menstruation on August 3 and 4 or within 3 days of the end of menstruation) (5)Those whose menstrual cycle is relatively stable (6)Those who can voluntarily consent to participate in the study in writing (7) Patients who have had a hemoglobin level of less than 13 g/dL (preferably less than 12 g/dL) in a previous blood test
Exclusion criteria
Exclusion criteria: (1) Those who are allergic to beans (soybeans, peas, and other legumes in general) (2) Those who are currently on medication for iron deficiency anemia. (3) Those who are currently receiving medication for any disease. (4) Those who are taking the food (soy milk) or health food containing the ingredients of this test food (5) Those with irregular menstrual cycles (6) Persons with serious diseases of glucose metabolism, lipid metabolism, liver function, kidney function, heart, circulatory system, respiratory system, endocrine system, immune system, nervous system, or mental disorders. (6) Those who have a history of serious diseases or mental disorders, and those who have a history of such diseases. (7) Those who have abnormal clinical laboratory values and are judged to have a problem with participation in the study. (8) Those who have a disease under treatment or a history of serious disease requiring medication. (9) Those who may develop allergies related to the study. (10)Those who are judged to be unsuitable as subjects based on the results of the answers to the lifestyle questionnaire. (11)Those who are participating in other clinical research at the time of the start of this study. (12) Those who are pregnant or plan to become pregnant or breastfeed during the study period (13) Patients with uterine fibroids or endometriosis (14)Those who are judged by the principal investigator to be unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in hemoglobin before and after intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Ferritin, red blood cells, serum iron, serum zinc, serum copper, hematocrit, TIBC, MCH, MCHC, anemia symptoms questionnaire, OSA sleep questionnaire, anti-fatigue questionnaire | — |
Countries
Japan
Contacts
Public ContactYoshihiro Otake
feileB Co.Ltd Clinical Trial Session
Outcome results
None listed